Results 71 to 80 of about 587 (136)

Experience with mildronate in cerebrovascular diseases

open access: yesМедицинский совет, 2015
Over the past years, results of various clinical trials of drugs demonstrating their efficacy in the treatment of cardiovascular diseases have been published. The article discusses the results of clinical use of Mildronate (meldonium) in the treatment of
N. V. Pizova
doaj   +1 more source

Mildronate (meldonium): First, do no harm

open access: yes, 2020
Meldonium (Mildronate) is used as a cardioprotective drug; however, it has not been officially approved anywhere outside the former Soviet Union (SU). The supposed action mechanism is based on the carnitine (Lcarnitine) lowering effect in muscular and ...
Jargin S.V.
core  

Analysis of results of survey on disciplinary liability for use of athletes and methods prohibited from the perspective of contemporary challenges of sport

open access: yesJournal of Education, Health and Sport, 2017
This paper concerns the analysis of disciplinary responsibility of sportsman for doping. Responsibility for doping has a constructive character of disciplinary, but in exceptional circumstances, the nature of legal liability under the Penal Code.
Michał Nowak
doaj   +1 more source

Crystal structures of binary compounds of meldonium 3-(1,1,1-trimethylhydrazin-1-ium-2-yl)propanoate with sodium bromide and sodium iodide

open access: yesActa Crystallographica Section E: Crystallographic Communications, 2018
3-(1,1,1-Trimethylhydrazin-1-ium-2-yl)propanoate (C6H14N2O2, M, more commonly known under its commercial names Meldonium or Mildronate) co-crystalizes with sodium bromide and sodium iodide forming polymeric hydrates poly[[tetra-μ-aqua-diaquabis[3-(1,1,1 ...
Alexander Y Nazarenko
doaj   +1 more source

Preventive cytoprotection in social diseases

open access: yesТерапевтический архив, 2015
Among many cytoprotective drugs, only a few of them that have a targeted metabolic effect include agents that partially inhibit oxidation of free fatty acids, the so-called p-FOX inhibitors (partial fatty acid oxidation inhibitors). Aim.
A S Skotnikov   +4 more
doaj  

EFFECTIVENESS OF MELDONIUMIN IN CHRONIC HEART FAILURE PATIENTS

open access: yesМедицинский совет, 2017
This article discusses the relevance of the high mortality of cardiovascular diseases (CVD) and their complications. Provides an overview of research conducted in the field of treatment of chronic heart failure and other cardiovascular diseases.
G. N. Gorokhovskaya   +4 more
doaj   +1 more source

Chemoreactomic analysis of citrulline malate molecules

open access: yesНеврология, нейропсихиатрия, психосоматика, 2017
Citrulline malate that is essential for the biosynthesis of arginine promotes dehydration of ammonium endotoxins, by participating in the urea cycle. The indications for the use of citrulline malate are functional asthenia, asthenic syndrome, overfatigue,
I. Yu. Torshin   +4 more
doaj   +1 more source

Review of pharmacological characteristics of Meldonium. Use of it in sports as doping.

open access: yes, 2018
Dissertação de Mestrado em Medicina do Desporto apresentada à Faculdade de MedicinaO Meldonium é um análogo estrutural do precursor da Carnitina, cujo mecanismo principal é inibir a síntese da Carnitina que é um transportador de FA do citoplasma para o ...
Yatsynych, Oksana
core  

Post-COVID syndrome: status of carbohydrate metabolism in patients with hypertension and stable ischemic heart disease

open access: yesMìžnarodnij Endokrinologìčnij Žurnal
Background. Post-COVID syndrome is associated with a wide range of chronic symptoms or conditions. Coronavirus di­sease 2019 (COVID-19) causes metabolic disorders such as hyperglycemia, insulin resistance.
O.V. Kuryata   +3 more
doaj   +1 more source

Unsolved problems of cytoprotective therapy in patients with coronary heart disease

open access: yesТерапевтический архив, 2015
The paper gives data on the proven efficiency of myocardial cytoprotection with the pFOX inhibitors trimetazidine and meldonium for coronary heart disease.
M E Statsenko   +2 more
doaj  

Home - About - Disclaimer - Privacy